Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNYNF – Research Report) and Fate ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €120.00. The ...

The French drugmaker said the vaccine it agreed to develop with Johnson & Johnson a year ago was “not sufficiently effective.

Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by ...

Johnson & Johnson said on Thursday it will discontinue a late-stage study of an experimental E.coli vaccine it was developing ...

Sanofi’s track record of creating effective solutions for people living with diabetes has lead to the development of the BGStarTM, a blood glucose monitoring device with the tools and a support ...

DelveInsight's Artificial Kidney Market Insights report provides the current and forecast market analysis, individual leading ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

On an adjusted basis, Biogen expects 2025 profit between $15.25 and $16.25 per share. It earned $16.47 in 2024 and analysts ...

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

Sanofi estimates that the annual cost for a typical patient will be around $280,000 per year before discounts or rebates, in line with other drugs used to treat rare, chronic diseases.